Patents by Inventor Torben Lessmann
Torben Lessmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220062273Abstract: The present invention relates to a conjugate or its pharmaceutically acceptable salt, wherein said conjugate is water-in-soluble and comprises a carrier moiety Z to which one or more moieties -L2-L1-D are conjugated, wherein each -L2- is individually a chemical bond or a spacer moiety; each -L1- is individually a linker moiety to which -D is reversibly and covalently conjugated; and each -D is individually a pattern recognition receptor agonist. It further relates to pharmaceutical compositions comprising such conjugate and to their use in the treatment of cell-proliferation disorders; and to related aspects.Type: ApplicationFiled: January 3, 2020Publication date: March 3, 2022Applicant: Ascendis Pharma Oncology Division A/SInventors: Kennett SPROGØE, Yang YANG-MALTEN, Torben LESSMANN, Nicola BISEK, Samuel WEISBROD, Sebastian STARK, Tobias VOIGT
-
Publication number: 20220054478Abstract: The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA is administered by intra-tissue administration, and wherein the protein levels of at least one cytokine selected from the group consisting of IL-6, CCL2 and EL-10 in plasma has a more than 10-fold lower maximum protein level within 24 hours compared to an equivalent molar dose of the corresponding free PRRA upon intra/tissue administration; and to related aspects.Type: ApplicationFiled: January 3, 2020Publication date: February 24, 2022Inventors: David B. ROSEN, Luis ZUNIGA, Juha PUNNONEN, Lars HOLTEN-ANDERSEN, Kennett SPROGØE, Yang YANG-MALTEN, Torben LESSMANN, Nicola BISEK, Samuel WEISBROD, Sebastian STARK, Tobias VOIGT
-
Publication number: 20220054477Abstract: The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) or its pharmaceutically acceptable salt or a pharmaceutical composition comprising such water-insoluble controlled-release PRRA or its pharmaceutical acceptable salt for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA, its pharmaceutically acceptable salt or the pharmaceutical composition is administered by intra-tissue administration, and wherein such intra-tissue administration results in local inflammation; and to related aspects.Type: ApplicationFiled: January 3, 2020Publication date: February 24, 2022Inventors: David B. ROSEN, Luis ZUNIGA, Juha PUNNONEN, Lars HOLTEN-ANDERSEN, Kennett SPROGØE, Yang YANG-MALTEN, Torben LESSMANN, Nicola BISEK, Samuel WEISBROD, Sebastian STARK, Tobias VOIGT
-
Publication number: 20220054476Abstract: The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) or its pharmaceutically acceptable salt or a pharmaceutical composition comprising such water-insoluble controlled-release PRRA or its pharmaceutical acceptable salt for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA, its pharmaceutically acceptable salt or the pharmaceutical composition is administered by intra-tissue administration, and wherein at least 25% of the amount of PRRA remains local in such tissue 3 days after administration; and to related aspects.Type: ApplicationFiled: January 3, 2020Publication date: February 24, 2022Inventors: David B. ROSEN, Luis ZUNIGA, Juha PUNNONEN, Lars HOLTEN-ANDERSEN, Kennett SPROGØE, Yang YANG-MALTEN, Torben LESSMANN, Nicola BISEK, Samuel WEISBROD, Sebastian STARK, Tobias VOIGT
-
Publication number: 20210220442Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: March 29, 2021Publication date: July 22, 2021Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
-
Patent number: 10960053Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: GrantFiled: September 28, 2018Date of Patent: March 30, 2021Assignee: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
-
Publication number: 20200390864Abstract: The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulation comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.Type: ApplicationFiled: August 28, 2020Publication date: December 17, 2020Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Thomas Kurpiers, Harald Rau, Evelyn Exner, Steen Jensen, Grethe Nørskov Rasmussen, Torben Lessmann, Thomas Wegge, Alina Hermann, Nina Schubert, Anna Splanemann, Joachim Zettler
-
Patent number: 10799563Abstract: The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.Type: GrantFiled: November 17, 2015Date of Patent: October 13, 2020Assignee: Ascendis Pharma Endocrinology DivisionInventors: Thomas Kurpiers, Harald Rau, Evelyn Exner, Steen Jensen, Grethe Nørskov Rasmussen, Torben Lessmann, Thomas Wegge, Alina Hermann, Nina Schubert, Anna Splanemann, Joachim Zettler
-
Patent number: 10729778Abstract: Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: GrantFiled: January 27, 2017Date of Patent: August 4, 2020Assignee: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Publication number: 20190192634Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: September 28, 2018Publication date: June 27, 2019Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
-
Publication number: 20190105400Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: ApplicationFiled: January 27, 2017Publication date: April 11, 2019Applicant: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogoe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Publication number: 20170354716Abstract: The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.Type: ApplicationFiled: November 17, 2015Publication date: December 14, 2017Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Thomas Kurpiers, Harald Rau, Evelyn Exner, Steen Jensen, Grethe Nørskov Rasmussen, Torben Lessmann, Thomas Wegge, Alina Hermann, Nina Schubert, Anna Splanemann, Joachim Zettler
-
Patent number: 9561285Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aromatic hydroxyl group is conjugated to one or more polymeric carriers via secondary carbamate-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.Type: GrantFiled: January 21, 2011Date of Patent: February 7, 2017Assignee: Ascendis Pharma ASInventors: Harald Rau, Torben Lessmann
-
Patent number: 9561287Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: GrantFiled: August 10, 2012Date of Patent: February 7, 2017Assignee: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Patent number: 9457066Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.Type: GrantFiled: May 14, 2015Date of Patent: October 4, 2016Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Harald Rau, Felix Cleemann, Ulrich Hersel, Silvia Kaden-Vagt, Torben Lessmann, Thomas Wegge
-
Patent number: 9265723Abstract: The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.Type: GrantFiled: July 30, 2010Date of Patent: February 23, 2016Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Kennett Sprogoe, Felix Cleemann, Ulrich Hersel, Silvia Kaden-Vagt, Torben Lessmann, Harald Rau, Thomas Wegge
-
Publication number: 20150258207Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.Type: ApplicationFiled: May 14, 2015Publication date: September 17, 2015Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Harald RAU, Felix CLEEMANN, Ulrich HERSEL, Silvia KADEN-VAGT, Torben LESSMANN, Thomas WEGGE
-
Publication number: 20150202317Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aliphatic amine group is conjugated to one or more polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.Type: ApplicationFiled: March 31, 2015Publication date: July 23, 2015Inventors: Harald Rau, Torben Leßmann
-
Patent number: 9062094Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aliphatic amine group is conjugated to one or more polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.Type: GrantFiled: January 21, 2011Date of Patent: June 23, 2015Assignee: Ascendis Pharma ASInventors: Harald Rau, Torben Lessmann
-
Publication number: 20140296150Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: ApplicationFiled: August 10, 2012Publication date: October 2, 2014Applicant: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler